Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

Fig. 2

Correlations between pre-afatinib cell-free DNA (cfDNA) methylation profile and progression-free survival (PFS) in patients with non-small cell lung cancer. Patients belonging to the initial cohort (n = 60) A and the validation cohort (n = 41) B are divided into a DNA hypermethylation group (Hyper) and a DNA hypomethylation group (Hypo) using the median values of the pre-afatinib cfDNA methylation levels in the initial cohort as the cutoff values (CV). Kaplan–Meier curves for PFS at 5 CpG sites showing the smallest P-values in the initial cohort using Log-rank test are shown. The Infinium assay probe ID for each CpG site and gene symbol are shown on the left side of each Kaplan–Meier curve

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us